CO4940457A1 - Composiciones farmaceuticas que comprenden sensibilizadores a insulina para tratamiento de la diabetes - Google Patents

Composiciones farmaceuticas que comprenden sensibilizadores a insulina para tratamiento de la diabetes

Info

Publication number
CO4940457A1
CO4940457A1 CO98034645A CO98034645A CO4940457A1 CO 4940457 A1 CO4940457 A1 CO 4940457A1 CO 98034645 A CO98034645 A CO 98034645A CO 98034645 A CO98034645 A CO 98034645A CO 4940457 A1 CO4940457 A1 CO 4940457A1
Authority
CO
Colombia
Prior art keywords
treatment
diabetes
pharmaceutical compositions
compositions including
insulin sensitizers
Prior art date
Application number
CO98034645A
Other languages
English (en)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311744&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4940457(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712854.0A external-priority patent/GB9712854D0/en
Priority claimed from GBGB9806710.1A external-priority patent/GB9806710D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of CO4940457A1 publication Critical patent/CO4940457A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una composición farmacéutica para el tratamiento de la diabetesmellitus y procesos asociados con la misma, la cual comprende un sensibilizador a la insulina, un secretagogo de insulina y un vehículo farmacéuticamente aceptable.
CO98034645A 1997-06-18 1998-06-18 Composiciones farmaceuticas que comprenden sensibilizadores a insulina para tratamiento de la diabetes CO4940457A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712854.0A GB9712854D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806710.1A GB9806710D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
CO4940457A1 true CO4940457A1 (es) 2000-07-24

Family

ID=26311744

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98034645A CO4940457A1 (es) 1997-06-18 1998-06-18 Composiciones farmaceuticas que comprenden sensibilizadores a insulina para tratamiento de la diabetes

Country Status (34)

Country Link
EP (3) EP1671637A3 (es)
JP (1) JP2001523270A (es)
KR (3) KR20010013840A (es)
CN (1) CN1168451C (es)
AP (1) AP1600A (es)
AR (2) AR008025A1 (es)
AT (1) ATE353654T1 (es)
AU (1) AU8539298A (es)
BG (2) BG64817B1 (es)
BR (1) BR9810142A (es)
CA (1) CA2294385C (es)
CO (1) CO4940457A1 (es)
CZ (1) CZ299310B6 (es)
DE (1) DE69837089T2 (es)
DZ (1) DZ2522A1 (es)
EA (1) EA003025B1 (es)
ES (1) ES2283064T3 (es)
HK (1) HK1028200A1 (es)
ID (1) ID24065A (es)
IL (1) IL133137A (es)
IN (1) IN189319B (es)
MA (1) MA24571A1 (es)
MY (1) MY125855A (es)
NO (3) NO326263B1 (es)
NZ (1) NZ501163A (es)
OA (1) OA11510A (es)
PE (1) PE108199A1 (es)
PL (2) PL198018B1 (es)
SK (1) SK286028B6 (es)
TR (1) TR199903096T2 (es)
TW (1) TW542717B (es)
UA (1) UA67743C2 (es)
UY (1) UY25048A1 (es)
WO (1) WO1998057649A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
BR0009934A (pt) 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
CA2389237A1 (en) 1999-11-01 2001-05-10 Wisconsin Alumni Research Foundation Abc1 modulation for the modulation of cholesterol transport
EP1349531A1 (en) 2001-01-12 2003-10-08 Sun Pharmaceuticals Industries Ltd. Spaced drug delivery system
KR100698595B1 (ko) * 2003-09-29 2007-03-21 보령제약 주식회사 무정형 또는 준결정형 글리메피리드, 이의 제조방법 및 무정형 또는 준결정형 글리메피리드를 포함하는 약학적조성물
HUE028576T2 (en) * 2003-10-31 2016-12-28 Takeda Pharmaceuticals Co Solid preparation containing pioglitazone, glimepiride and polyoxyethylene sorbitan fatty acid ester
TWI384985B (zh) 2005-12-22 2013-02-11 Takeda Pharmaceutical 固體製劑
CN104158867B (zh) * 2014-08-06 2017-05-17 电子科技大学 一种基于wave协议的信息多跳转发方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
PL296945A1 (es) 1990-07-03 1992-07-13 Yamanouchi Pharma Co Ltd
KR930701420A (ko) 1990-08-23 1993-06-11 알렌 제이. 스피겔 혈당저하제로서의 하이드록시우레아 유도체
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−2,4−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
SK109993A3 (en) 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
TW222626B (es) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DK0601001T3 (da) * 1991-08-26 1997-10-20 Upjohn Co Flydende næringsmiddelprodukt indeholdende 3-guanidinopropionsyre.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
JPH07505647A (ja) 1992-04-10 1995-06-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 複素環化合物および2型糖尿病の治療におけるそれらの使用
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
CA2139442A1 (en) 1992-07-03 1994-01-20 David Haigh Heterocyclic compounds as pharmaceutical
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
UA67743C2 (uk) 2004-07-15
BG64817B1 (bg) 2006-05-31
AP9901717A0 (en) 1999-12-31
EP1671637A3 (en) 2007-12-19
CA2294385C (en) 2007-06-05
SK179199A3 (en) 2000-11-07
NO996264D0 (no) 1999-12-17
KR20080011356A (ko) 2008-02-01
IL133137A (en) 2004-02-08
NO996264L (no) 2000-02-17
TW542717B (en) 2003-07-21
PL337510A1 (en) 2000-08-28
DE69837089D1 (de) 2007-03-29
HK1028200A1 (en) 2001-02-09
ES2283064T3 (es) 2007-10-16
EP0999845B1 (en) 2007-02-14
CZ299310B6 (cs) 2008-06-18
MY125855A (en) 2006-08-30
OA11510A (en) 2004-02-03
DE69837089T2 (de) 2007-06-21
IN189319B (es) 2003-02-08
DZ2522A1 (fr) 2003-02-01
TR199903096T2 (xx) 2000-08-21
EP2266576A1 (en) 2010-12-29
SK286028B6 (sk) 2008-01-07
BR9810142A (pt) 2000-08-08
IL133137A0 (en) 2001-03-19
JP2001523270A (ja) 2001-11-20
AR008025A1 (es) 1999-12-09
BG104058A (en) 2000-10-31
NO2009002I1 (no) 2009-03-02
EA200000039A1 (ru) 2000-08-28
AP1600A (en) 2006-04-28
CZ9904577A3 (en) 2001-05-16
KR20010013840A (ko) 2001-02-26
EP0999845A1 (en) 2000-05-17
BG109397A (bg) 2006-05-31
UY25048A1 (es) 2000-09-29
ID24065A (id) 2000-07-06
AU8539298A (en) 1999-01-04
PL198018B1 (pl) 2008-05-30
EP1671637A2 (en) 2006-06-21
EA003025B1 (ru) 2002-12-26
MA24571A1 (fr) 1998-12-31
ATE353654T1 (de) 2007-03-15
NO326263B1 (no) 2008-10-27
KR20070011651A (ko) 2007-01-24
NZ501163A (en) 2002-02-01
AR012996A1 (es) 2000-11-22
CN1168451C (zh) 2004-09-29
PE108199A1 (es) 2000-01-14
CA2294385A1 (en) 1998-12-23
NO20083276L (no) 2000-02-17
WO1998057649A1 (en) 1998-12-23
CN1260719A (zh) 2000-07-19

Similar Documents

Publication Publication Date Title
EE200000320A (et) Uudsed ühendid
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
YU10699A (sh) Upotreba glp-1, glp-1 analoga i glp-1 derivata za proizvodnju leka
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
FR2708606B1 (fr) Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
DK0994710T3 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzhydrylpiperazin og en cyclodextrin
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
WO2001045678A3 (de) Arzneimittel, verfahren zu dessen herstellung und dessen verwendung
GR3031521T3 (en) Use of 2-amino-6-a-propylamino-4,5,6,7-tetrahydrobenzothiazole (pramipexol) as an anti-depressant drug.
ES2071663T3 (es) Analogo de fluoxetina.
CO4940457A1 (es) Composiciones farmaceuticas que comprenden sensibilizadores a insulina para tratamiento de la diabetes
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
ATE450254T1 (de) Schwimmende pharmazeutische zusammensetzung mit einer aktiven phase und einer inaktiven phase
AR019724A2 (es) Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas
NO985571L (no) Legemiddel for autoimmunsykdommer
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
FI884545A0 (fi) Farmaceutisk komposition, som innehaoller avsvaellande piperidinoalkanolfoereningar.
UY25103A1 (es) Composición para el tratamiento de diabetes mellitus
PT1001942E (pt) Poli-hidroxibutilpirazinas sua preparacao e medicamentos que as contem
AR012341A1 (es) Compuesto derivados de estradienos, composicion farmaceutica que los contiene y el uso de los mismos para la fabricacion de medicamentos
NO20050445L (no) Synergistisk interaksjon mellom abacavir og alovudin
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
DK1023059T3 (da) Farmaceutiske præparater